Stocktoria

Embecta Corp. EMBC

Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2022-03-21 · LEI

Embecta Corp. financials (annual)

Revenue
$1.17B $1.13B $1.12B $1.12B $1.08B 20212022202320242025
Net income
$414.8M $223.6M $70.4M $78.3M $95.4M 20212022202320242025
Free cash flow
$419.5M $388.6M $41.2M $19.9M $182.4M 20212022202320242025

Bars are annual figures from 2021 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021
Revenue$1.1B$1.1B$1.1B$1.1B$1.2B
Gross profit$676.8M$735.2M$749.9M$774.9M$800.4M
R&D expense$37.3M$78.8M$85.2M$66.9M$63.3M
SG&A expense$332.0M$365.1M$341.3M$294.8M$240.3M
Operating income$242.1M$166.8M$221.5M$309.6M$492.0M
Income tax$40.9M-$34.1M$35.3M$33.0M$80.1M
Net income$95.4M$78.3M$70.4M$223.6M$414.8M
EPS (diluted)$1.62$1.34$1.22$3.89$7.28
Operating cash flow$191.7M$35.7M$67.7M$412.2M$456.3M
Free cash flow$182.4M$19.9M$41.2M$388.6M$419.5M
Cash & equivalents$225.5M$267.5M$326.3M$330.9M$0
Inventory$178.6M$171.5M$152.1M$122.8M$118.0M
Total assets$1.1B$1.3B$1.2B$1.1B$788.0M
Shareholders' equity-$650.6M-$738.3M-$821.7M-$891.4M$594.3M

Growth · year-over-year · Revenue CAGR -1.9%

MetricFY2025FY2024FY2023FY2022FY2021
Revenue growth-3.8%+0.2%-0.8%-3.1%
Net income growth+21.8%+11.2%-68.5%-46.1%
EPS growth+20.9%+9.8%-68.6%-46.6%
Free cash flow growth+816.6%-51.7%-89.4%-7.4%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.